Satori Technology
Satori is developing innovative disease modifying therapies that target the underlying neurotoxic mechanisms of Alzheimer’s disease.
Our current focus is on targeting the amyloid pathway and key toxic mediators that cause neuronal damage and lead to Alzheimer's disease progression.
Satori’s proprietary technologies are directed towards discrete steps in the neurotoxic cascade.
Alzheimer's Disease
Alzheimer's disease is among the greatest of unmet medical needs. Current treatments for Alzheimer's disease address only symptoms without effectively treating the underlying causes and promoters of disease. Ongoing research has provided increasingly clearer guidance on how to, for the first time, discover and develop truly disease-modifying therapeutics for these diseases.
In Alzheimer's disease, protein misfolding results in a cascade of events that includes the formation of the pathological "senile plaques" that are the singular hallmark characteristic of this disease. Human genetics, animal studies, protein biochemistry, cellular and molecular biology, and recent clinical studies consistently point to specific cellular processes that produce pro-toxic proteins that misfold and cause cellular dysfunction. Satori is developing drugs that target these disease-specific processes to limit the production of toxic proteins and block their pathological effects on brain function.
